A Phase 1 interventional study of SBRT in Nonsmall Cell Lung Cancer Stage, sponsored by Georgetown University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Georgetown University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,888th largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 134 that started in 2026, is one of 928 in phase 1, reaches primary completion later than 855 of the 893 other live ones, and was the 3,355th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,415 · Phase 2 1,596 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 134 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 3,001 interventional studies, 100 across the 246 observational. Of the 2,302 that completed or were terminated, 1,054 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,741 of 3,374 have an industry lead sponsor. The 10 most frequent:
Georgetown University is the lead sponsor of 292 studies on the registry; 40 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.
Georgetown University has 5 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
267 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
Add all 267 to your calendar (.ics) → With an account.
Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the amount of serious side effects from SBRT. Participants will
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4D-CT (computed tomography) scans will be required to evaluate tumor motion and verification at time of simulation:
○ Screening for ultra-central tumor deformation between inhalation and exhalation extremities will be performed via 4D-CT to avoid inappropriate margins for significant tumor motion or deformation.
Ultra-central tumors must include:
o Gross Tumor Volume (GTV) or Planning Target Volume (PTV) located within 1 cm (centimeter) of the Proximal Bronchial Tree (PBT) and/or at least one of the following: (1) GTV or protocol PTV within 1 cm of the PBT; or (2) GTV within 5 mm of or abutting/overlapping the esophagus, heart/pericardium, aorta, pulmonary artery, or pulmonary vein.
Patients are eligible to receive SBRT:
Patients are eligible to receive radiation therapy:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: SBRT
50 Grays (Gy) delivered in 5 fractions, delivered using Cyberknife with Synchrony motion tracking, every other day over 2 weeks.
Cumulative incidence of grade 3 or higher toxicity following SBRT with CyberKnife regimen with real-time motion tracking for ultra-central NSCLC.
The primary safety endpoint is the cumulative incidence of acute or late grade ≥3 AEs occurring within 12 months and assessed as possibly, probably, or definitely related to protocol treatment. AEs will be graded using the NCI CTCAE version 6.0. Prespecified thoracic AEs include dyspnea, cough, pneumonitis, lung infection, atelectasis, bronchial stenosis or obstruction, bronchopulmonary hemorrhage or hemoptysis, fistula, dysphagia or esophagitis, pleural or pericardial effusion, and chest pain.
Time frame: Patients will be assessed for toxicity throughout treatment with radiation therapy (RT). Following RT, all participants will be evaluated through 12 months for the primary safety endpoint and will continue protocol safety follow-up through 5 years.
Local control (LC)
LC will be calculated using the cumulative incidence method and reported along with a 95% exact binomial confidence interval (CI).
Time frame: Until Trial Completed (up to 5 years)
Regional nodal progression
The regional nodal progression is defined as the length of time from radiation completion of the first documented presence of enlarged lymph nodes \>1 cm \[short axis\] in the hilum or mediastinum and biopsy confirmed. The Kaplan-Meier method will be used for the analyses, and the median regional nodal progression free time with 95% CI will be reported, respectively, if available.
Time frame: Until Trial Completed (up to 5 years)
Distant metastasis-free survival (DMFS)
DMFS is defined as the length of time, from radiation completion to the first evidence of clinical distant metastatic spread of NSCLC outside of the lung cavity or death, whichever occurs first. Patients who are alive and free from clinical distant metastasis will be censored at the date of last follow-up for DMFS. The Kaplan-Meier method will be used for the analyses, and the median DMFS with 95% CI will be reported, respectively, if available.
Time frame: Until trial completed (up to 5 years)
Progression-free survival (PFS)
PFS is defined as the length of time, from radiation completion to the first evidence of clinical/radiographic progression, biopsy confirmation when feasible, distant metastasis, or death, whichever comes first. Patients who are alive and free from disease progression will be censored at the date of last follow-up or date of death, whichever occurs first. SOC PET/CT imaging results will be reviewed and collected. The Kaplan-Meier method will be used for the analyses, and the median PFS with 95% CI will be reported, respectively, if available.
Time frame: From baseline through the follow up period at 3, 6, 9, 12, 18, 24 months followed annually thereafter up to 5 years.
Overall survival (OS)
OS is defined as the length of time, from radiation completion, a patient lives until death. Patients who are alive will be censored at either the date of last follow-up or date of death, whichever occurs first. The Kaplan-Meier method will be used for the analyses, and the median survival time with 95% CI will be reported, respectively, if available.
Time frame: Up to 5 years
Incidence of treatment related acute and late grade 2 or higher toxicity and late grade ≥3 toxicity
The incidence of treatment related acute and late grade ≥2 and late grade ≥3 AEs (AESI) will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 or severity grade when CTCAE grading does not exist. Grade 1 to 5 will be used to characterize the severity of the AE. If CTCAE grading does not exist for an AE, the severity of mild, moderate, severe, life-threatening and death due to the AE, corresponding respectively to Grades 1 - 5, will be used.
Time frame: From the start of radiation treatment throught 12 months and 24 months.
Patient-Reported Quality of Life Outcomes (QoL)
Patient-reported QoL outcomes through designated questionnaires. The EORTC QoL questionnaire (QLQ)-C30 is a 30-item form for lung cancer patients that incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), a global health status/ QoL scale, and several single items assessing additional symptoms commonly experienced by cancer patients. The EORTC QLQ-LC13 is a clinically validated tool to assess disease and treatment specific symptoms in lung cancer patients that will participate in clinical trials. Quality of life outcomes will be summarized over time using descriptive statistics and graphical displays. The Wilcoxon signed-rank test will be used for comparisons of QoL between follow-up time points and baseline. Repeated measure models may be employed to assess changes in QoL outcomes over time if deemed necessary.
Time frame: Pre-radiation/baseline, 3, 6, 9, 12, 18, 24 months post-radiation and then annually thereafter until 5 years.
Pulmonary Function Testing - Forced Expiratory Volume in One Second (FEV1)
The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.
Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.
Pulmonary Function Testing - FVC (Forced Vital Capacity)
The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.
Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.
Pulmonary Function Testing - Diffusing Capacity for Carbon Monoxide (DLCO)
The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.
Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.
Pulmonary Function Testing - TLC (total lung capacity)
The pulmonary function testing (PFT) changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.
Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.
Correlation of Dose-volume histogram (DVH) parameters for organs-at-risk (OARs) with observed toxicities and local control
DVH parameters for OARs will be analyzed with their correlation with observed toxicities and local control. Descriptive statistics will be presented for DVH parameters for organs-at-risk (OARs). Two-sided t-test or Mann-Whitney test, ANOVA or Kruskal-Wallis test will be utilized for continuous DHV parameters and Chi-square test or Fisher's exact test will be used for categorical DHV parameters to assess associations between DVH parameters and toxicity and LC, respectively.
Time frame: through 12 months post-radiation
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2031, 60 months later.
Of 225 non-industry phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 60 months is above that.
Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →